

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-8 (canceled).

Claim 9 (currently amended): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising a recombinant expression construct comprising at least one promoter operably linked to a nucleic acid sequence encoding a cell surface receptor antigen, a nucleic acid sequence encoding a first immune response altering molecule and a nucleic acid sequence encoding a second immune response altering molecule, ~~according to any one of claims 1-8~~ wherein the cell surface receptor antigen is Her2/Neu, the first immune response altering molecule is 4-1BB ligand, and the second immune response altering molecule is CD86/B7.2.

Claim 10 (currently amended): The composition of any one of claims 9 and 12-14, wherein Her2/Neu comprises a polypeptide sequence selected from the group consisting of sequences set forth in GenBank Acc. Nos. X03363 (as set forth in SEQ ID NO: 6), M17730 (as set forth in SEQ ID NO: 8), and SEG_HUMHER20 (as set forth in SEQ ID NO: 9).

Claim 11 (currently amended): The composition of any one of claims 9 and 12-14, wherein CD86/B7.2 comprises a polypeptide sequence selected from the group consisting of sequences set forth in GenBank Acc. Nos. AF099105, SEG_MMB72G (as set forth in SEQ ID NOS: 11-15), U39466 (as set forth in SEQ ID NOS: 16-20), U04343 (as set forth in SEQ ID NO: 22), SEG_HSB725, L25606 (as set forth in SEQ ID NO: 24), and L25259 (as set forth in SEQ ID NO: 26).

Claim 12 (new): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising:

a) a first recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a cell surface receptor antigen and a nucleic acid sequence encoding a first immune response altering molecule; and

b) a second recombinant expression construct containing a promoter operably linked to a nucleic acid sequence encoding a second immune response altering molecule,

wherein the cell surface receptor antigen is Her2/Neu, the first immune response altering molecule is 4-1BB ligand, and the second immune response altering molecule is CD86/B7.2.

Claim 13 (new): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising:

a) a first recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a cell surface receptor antigen;

b) a second recombinant expression construct containing a promoter operably linked to a nucleic acid sequence encoding a first immune response altering molecule; and

c) a third recombinant expression construct containing a promoter operably linked to a nucleic acid sequence encoding a second immune response altering molecule,

wherein the cell surface receptor antigen is Her2/Neu, the first immune response altering molecule is 4-1BB ligand, and the second immune response altering molecule is CD86/B7.2.

Claim 14 (new): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising:

a) a first recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a cell surface receptor antigen; and

b) a second recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a first immune response altering molecule and a nucleic acid sequence encoding a second immune response altering molecule,

wherein the cell surface receptor antigen is Her2/Neu, the first immune response altering molecule is 4-1BB ligand, and the second immune response altering molecule is CD86/B7.2.

Claim 15 (new): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising expression products of the recombinant expression constructs which comprise the composition according to any one of claims 9 and 12-14.